期刊文献+

沙培林联合顺铂腔内给药治疗恶性胸腔积液 被引量:3

Intrapleural Therapy Combined with OK-432 and DDP for Malignant Pleural Effusion
暂未订购
导出
摘要 目的观察沙培林(OK-432)联合顺铂(DDP)腔内给药治疗恶性胸腔积液的近期疗效和不良反应.方法对42例恶性胸腔积液患者先采用美国Arrow公司生产的一次性单腔中心静脉导管进行胸腔穿刺置管闭式引流胸水,再给予胸腔内注药.将42例随机分成两组,治疗组(n=20)采用沙培林加顺铂,对照组(n=22)单用顺铂.顺铂每次注入60~80 mg,每周注射1次,沙培林每周连续3 d分别注入5KE、10KE、10KE,2周为1周期.结果治疗组有效率90%(18/20),对照组有效率59.1%(13/22),两组间有显著性差异(P<0.05).结论胸腔闭式引流后联合注入沙培林加顺铂治疗恶性胸腔积液优于单用顺铂治疗,疗效肯定,是控制恶性胸腔积液的有效方法. Objective To evaluate the response and adverse reactions of OK -432 and cisplatin (DDP) in the treatment of malignant pleural effusion. Methods The single lumen central venous catheters made by the Arrow Company were applied in cases with malignant pleural effusion for the closed thoracic drainage. 42 cases were randomly divided into two groups: the treatment group ( n = 20) received the intracavity injection of OK - 432 and DDP, while the contrast group ( n = 22) treated only with DDP. 60 ~ 80mg of DDP was given one time a week, and 5KE, 10KE and 10KE of OK-432 was given in successive three days every week. The period of treatment was 2 weeks. Results The response rate was 90% (18/20) and 59.1% (13/22) in the treatment group and the contrast group respectively. There was significant difference between the two groups ( P 〈 0.05). Conclusions The curative effect of the combined therapy with OK - 432 and DDP after draining the pleural fluid is better than that of the single drug of DDP in patients with malignant pleural effusion. This method is more effective for the malignant pleural effusion.
作者 李建军 麻青
出处 《实用全科医学》 2006年第3期306-307,共2页 Applied Journal Of General Practice
关键词 沙培林 顺铂 恶性胸腔积液 胸腔闭式引流 OK - 432 Cisplatin (DDP) Malignant pleural effusion Closed thoracic drainage
  • 相关文献

参考文献3

二级参考文献12

共引文献39

同被引文献23

  • 1陈衍智,李萍萍,杨丽芳,刘培红.白细胞介素Ⅱ联合顺铂治疗恶性胸腔积液[J].临床肿瘤学杂志,2004,9(4):337-339. 被引量:21
  • 2魏菊梅,袁云芳,房丽华.卡铂和顺铂腔内用药治疗恶性胸腹水的近期疗效观察[J].河南肿瘤学杂志,1995,8(3):199-201. 被引量:3
  • 3陈卓明,黄祖栋,何晓洪,黄羽,苏贞栋.恶性胸水胸腔化疗后胞必佳治疗疗效观察[J].实用肿瘤学杂志,2006,20(5):408-409. 被引量:3
  • 4王衍富,张芳.恶性胸腔积液的诊断进展[J].实用心脑肺血管病杂志,2006,14(9):681-682. 被引量:2
  • 5Katano M, Morisaki T. The past,the present and future of the OK-432 therapy for patients with malignant effusions [J]. Antieancer Res, 1998,18(5D) :3917.
  • 6Tanaka A, Sato T. Adhesion thrapy for malignant pleural effusion( in- trapleural administration of Ok-432 with minoncycline ) [ J ]. Nihonkokyuki Gakkai Zasshi,1999,37(7) :531-537.
  • 7Katano M,Morisaki T.The past,the present and future of the OK-432 therapy for patients with malignant effusions[J].Anticancer Res,1998,18(5D):3 917.
  • 8Tanaka A,Sato T.Adhesion thrapy for malignant pleural effusion(intrapleural administration of Ok-432 with minoncycline)[J].Nihonkokyuki Gakkai Zasshi,1999,37(7):531-537.
  • 9Ahmad Z,Krishnadas R,Froeschle P.Pleural effusion:diagnosis and management[J].J Perioper Pract,2009 Aug;19(8):242-247.
  • 10Garcia Sevila R,Barroso E,Martin C,et al.Lymphangitic carcinomatosis as a cause of malignant transient pleural transudate[J].Case Report Med,2009,598741.Epub 2009:8.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部